Open trials


Accrual overview of ongoing ETOP trials

Enroled  Randomised Enroled under protocol version Randomised Randomised Enroled
 v1.0  v2.0  v.3.0
225 137  12  46 36 144 152 3



ETOP 13-18 BEAT-meso is multicentre randomised phase III trial comparing atezolizumab plus bevacizumab and standard chemotherapy versus bevacizumab and standard chemotherapy as first-line treatment for advanced malignant pleural mesothelioma We are currently finalizing the trial protocol and hope to be able to activate this trial within the next weeks.



ETOP 10-16 BOOSTER is a randomised, open-label, phase II trial comparing the third generation EGFR TKI osimertinib in combination with the angiogenesis inhibitor bevacizumab versus osimertinib alone as second-line treatment in advanced NSCLC with activating EGFR and T790M resistance mutation. Ireland, the Netherlands, Spain, Switzerland, as well as, South Korea, and Singapore are participating countries in this trial. The trial is recruiting very well and we estimate that we will reach the accrual goal of 154 randomized patient early next year.



ETOP 12-17 ALERT-lung is a single arm phase II trial, evaluating the activity of alectinib in pre-treated patients with RET-rearranged advanced NSCLC. The primary objective is to assess the efficacy of alectinib in terms of overall response. The trial will be conducted in Belgium, France, Germany, Ireland, Italy, the Netherlands, Portugal, Slovenia, Spain and Switzerland. The trial protocol was release in September 2017. All participating Swiss sites and most sites in Spain are activated for the trial, with the other sites and countries following rapidly.



ETOP 6-14 NICOLAS is a feasibility trial evaluating the addition of anti-PD-1 nivolumab to standard first-line chemotherapy and radiotherapy in locally advanced stage IIIA/B Non-Small Cell Lung Carcinoma. As of 9 August 2018, the overall accrual goal of 94 patients has been reached and the accrual suspended. ETOP is currently working on a protocol amendment to include an additional patient cohort and we hope that we will soon be able reopen the accrual into the NICOLAS trial.